 WESTMER, Colo., May 05, 2021 GLOBE NEWSWIRE -- ARCA biopharma, Inc. Nasdaq: ABIO, a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development. 